219 related articles for article (PubMed ID: 26823825)
1. DAPK1, MGMT and RARB promoter methylation as biomarkers for high-grade cervical lesions.
Sun Y; Li S; Shen K; Ye S; Cao D; Yang J
Int J Clin Exp Pathol; 2015; 8(11):14939-45. PubMed ID: 26823825
[TBL] [Abstract][Full Text] [Related]
2. [Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].
Zhong ZJ; Yang JX; Cao DY; Sun Y; Sun LL; Cheng XM; Chen J; Lang JH; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):196-200. PubMed ID: 22781071
[TBL] [Abstract][Full Text] [Related]
3. Population-based case-control study on DAPK1, RAR-β2 and MGMT methylation in liquid-based cytology.
Sun LL; Cao DY; Yang JX; Li H; Zhou XR; Song ZQ; Cheng XM; Chen J; Shen K
Arch Gynecol Obstet; 2012 May; 285(5):1433-9. PubMed ID: 22116316
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
Banzai C; Nishino K; Quan J; Yoshihara K; Sekine M; Yahata T; Tanaka K;
Int J Clin Oncol; 2014 Feb; 19(1):127-32. PubMed ID: 23494221
[TBL] [Abstract][Full Text] [Related]
5. Limited Role of Promoter Methylation of
Sun LL; Liu Y; Sun X; Pan L; Wu D; Wang YD
Chin Med J (Engl); 2018 Apr; 131(8):939-944. PubMed ID: 29664054
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
[TBL] [Abstract][Full Text] [Related]
7. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
8. Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis.
Flatley JE; McNeir K; Balasubramani L; Tidy J; Stuart EL; Young TA; Powers HJ
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2782-9. PubMed ID: 19755648
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis.
Gustafson KS; Furth EE; Heitjan DF; Fansler ZB; Clark DP
Cancer; 2004 Aug; 102(4):259-68. PubMed ID: 15368319
[TBL] [Abstract][Full Text] [Related]
10. Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy.
Lim EH; Ng SL; Li JL; Chang AR; Ng J; Ilancheran A; Low J; Quek SC; Tay EH
Gynecol Oncol; 2010 Nov; 119(2):225-31. PubMed ID: 20708786
[TBL] [Abstract][Full Text] [Related]
11. Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.
Iliopoulos D; Oikonomou P; Messinis I; Tsezou A
Oncol Rep; 2009 Jul; 22(1):199-204. PubMed ID: 19513524
[TBL] [Abstract][Full Text] [Related]
12. Predicting cervical intraepithelial neoplasia recurrence in HIV-infected and -noninfected women by detecting aberrant promoter methylation in the CDH1, TIMP3, and MGMT genes.
Teixeira da Costa Lodi C; Michelin MA; Miranda Lima MI; Murta EFC; Braga LDC; Montes L; Melo VH
Arch Gynecol Obstet; 2018 Nov; 298(5):971-979. PubMed ID: 30218185
[TBL] [Abstract][Full Text] [Related]
13. Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
Huang J; Luo JY; Tan HZ
PLoS One; 2019; 14(10):e0222772. PubMed ID: 31574102
[TBL] [Abstract][Full Text] [Related]
14. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Gynecol Oncol; 2010 Jan; 116(1):99-104. PubMed ID: 19836067
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Kweon SS; Fackler MJ; Sukumar S
Virchows Arch; 2010 Jul; 457(1):35-42. PubMed ID: 20496080
[TBL] [Abstract][Full Text] [Related]
16. JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix.
Yin A; Zhang Q; Kong X; Jia L; Yang Z; Meng L; Li L; Wang X; Qiao Y; Lu N; Yang Q; Shen K; Kong B
Oncotarget; 2015 Dec; 6(42):44373-87. PubMed ID: 26517242
[TBL] [Abstract][Full Text] [Related]
17. Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia.
Wijetunga NA; Belbin TJ; Burk RD; Whitney K; Abadi M; Greally JM; Einstein MH; Schlecht NF
Gynecol Oncol; 2016 Sep; 142(3):566-73. PubMed ID: 27401842
[TBL] [Abstract][Full Text] [Related]
18. Real-time colorimetric detection of DNA methylation of the
Huang J; Liou YL; Kang YN; Tan ZR; Peng MJ; Zhou HH
Int J Nanomedicine; 2016; 11():5335-5347. PubMed ID: 27789946
[TBL] [Abstract][Full Text] [Related]
19. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.
Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; van der Wal JE; Wisman GB; Roodenburg JL; Schuuring E
Epigenetics; 2015; 10(9):850-60. PubMed ID: 26213212
[TBL] [Abstract][Full Text] [Related]
20. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
